FDA Halts Release of New Drug Rejection Letters, Will Formalize Policy

The U.S. Food and Drug Administration has paused the release of letters that explain its reasons for rejecting new drug applications, according to a report from Fierce Biotech. The agency is working to formalize its policy on these documents.

The pause follows a citizen’s petition filed in April by an unnamed pharmaceutical company. The FDA had previously been releasing these letters under a controversial policy. The agency will not issue new rejection letters until it completes its policy review.

The letters, known as complete response letters, detail the scientific or regulatory deficiencies that led to a drug’s rejection. Drug developers and investors closely watch them for insight into the FDA’s thinking. The pause introduces uncertainty into the regulatory information pipeline for companies awaiting decisions on their applications.

Why This Matters for Biotech

The FDA’s practice of releasing rejection letters was a relatively recent transparency measure. It allowed other companies to learn from the agency’s reasoning without having to go through the same rejection process. The pause could delay the availability of that information. For the biotech industry, any change in the flow of regulatory feedback affects how companies plan their development strategies, especially for novel therapies where the FDA’s standards are still evolving.

Source: original report